NPO Petrovax Pharm is a leading research and manufacturing company in Russia, producing pharmaceuticals and vaccines. Interros acquired a controlling stake in the company in 2013.
The company was founded in 1996 by a team of Russian researchers to develop, produce and commercialize original innovative pharmaceuticals.
The company’s main areas of focus are manufacturing flu vaccine to meet the national immunization calendar, and developing and producing immunobiologicals and long-acting nanobio drugs.
The company’s product line consists exclusively of innovative drugs and vaccines that NPO Petrovax Pharm successfully markets in Russia and the countries of the CIS and the EU.
February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.
Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.
June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-
July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.
August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.
October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.
Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.
Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.
At the beginning of the year NPO Petrovax Pharm invested over 900 million rubles in a new production line that meets all GMP requirements, allowing a two-and-
In March, NPO Petrovax Pharm was again certified by the Ministry of Industry and Trade as having a manufacturing and management systems compliant with the GMP quality requirements, thus confirming that the company meets their high standards. Soon after, Petrovax Pharm announced an extension of the recommended age group for the use of Polyoxidonium ® to include children starting at 3 years old.
In June, under the sponsorship of NPO Petrovax Pharm and the Interros Group, the
In July, the company received a report on the successful conclusion of the EU
In August, NPO Petrovax Pharm began exporting more than 2 million doses of the Grippol Plus ® flu vaccine to Kazakhstan. In October, a
In the middle of October the first batches of Metalize ®, a drug to treat acute myocardial infarction, became available to patients in Russia. Production was localized in Russia in partnership with Boehringer Ingelheim. At the end of the month, Petrovax Pharm received an ISO 9001:2015 management quality control system compliance certificate. In addition to the main ISO 9001:2015 certificate, Petrovax also obtained an IQNet single international certificate.
At the end of the year, the company donated 200 thousand doses of Grippol Plus® vaccine to clinics in the Moscow region to prevent flu epidemic.
Polyoxidonium ® won Russian Pharma Awards 2017, an annual competition held for the 6th time, in the «Drug of Choice to Prevent and Treat Acute Respiratory Infection and Flu in Children» category.
In February 2018, NPO Petrovax Pharm received an award for «Dynamic Business Development» from the Russian Union of Industrialists and Entrepreneurs. The same month, Boehringer Ingelheim and Petrovax Pharm completed another phase in the process to begin domestic production of advanced thrombolytic drugs in Russia. The first supplies of Aktilise® for treatment of ischemic strokes have been delivered to Russian clinics.
In May 2018, Polyoxidonium won the Smartpharma Awards 2018. It received more votes than any other product in the category «Recommendation of the Year for Treatment of Acute Respiratory Infection and Flu in Children 3 years and older», putting it in first place.
In July, NPO Petrovax Pharm obtained a registration certificate to sell Grippol®Quadrivalent, the first quadrivalent influenza vaccine in Russia. This is the most advanced of the existing flu vaccines in the world, both highly effective and safe. The vaccine offers protection from four strains of influenza.
In September, NPO Petrovax pharmaceutical complex produced the first batch of
In November, Petrovax Pharm won
In March, Petrovax won the «Russian Business Guide. PEOPLE OF THE YEAR» award in the "Pharmaceuticals" nomination for its contribution to the development of the Russian economy and active entrepreneurship.
At the beginning of April, at the INFLUENZA VACCINES FOR THE WORLD - international conference on influenza prevention held in Edinburgh - world experts evaluated the efficacy and safety of Grippol® vaccines with the Polyoxidonium adjuvant. The European independent FluConsult Company confirmed the data on the mechanisms of action of Polyoxidonium in the vaccine, previously provided by Russian researchers.
In June 2019, Petrovax confirmed the compliance of the production and Quality Management System (QMS) with EU GMP rules. The certificate was issued following an audit conducted by the State Institute of Quality Control of Medicines (SUKL, Slovakia).
In July, Petrovax received permission to commission the second production building in the urban district of Podolsk, Moscow Region. The new building includes two production lines for the manufacturing of substances, solid, soft and liquid finished dosage forms. More than 1 billion rubles were invested in its construction.
In August, the company launched Velson® - a state-of-the-art medication for sleep normalization and arranging human biorhythms.
In October, Petrovax completed on schedule the supply of the Grippol® Plus vaccine to the national market and the EAEU countries. In anticipation of the 2019-2020 epidemic season, the company isupplied more than 8 million doses of the Grippol® Plus vaccine for the Russian commercial market and for export. The company exported towards Belarus, Kazakhstan, Kyrgyzstan and Uzbekistan more than 6 million doses of vaccine.